THANK YOU FOR SUBSCRIBING
THANK YOU FOR SUBSCRIBING
BioPlx has made a groundbreaking clinical demonstration of efficacy and safety in their clinical trials back in their 2017 clinical trial by controlling recolonization following decolonization and preventing the recurrence of MRSA amongst medical professionals. Upon conclusion of the trial, BioPlx was able to exclude MRSA from the micro biome of all participants and prevent its recurrence for six months after only a single decolonization and recolonization application. BioPlx’s strategies involve targeting ‘bad bugs’ such as MRSA, decolonizing it from the patient’s microbiome, using appropriate treatments such as chlorhexidine, and introduce a protective BioPlx therapeutic to prevent relapse. “In our clinical trial, we showed that we could protect on a single application for up to six months, which is durability far beyond what the current clinical state of the art is,” further explains Starzl.Our mission at BioPlx is to prevent infectious disease through the management of the microbiome and make sure that people stay disease-free longer under more cost-effective regimens that are more sustainable
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info